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Abstract: The increasing importance to determine bioactive peptide hormones such as insulin, its
synthetic analogs, and C-peptide in urine samples represents an analytical challenge. The phys-
iological concentrations of insulin in urine are commonly found at sub-ng/mL levels and thus
represent a complex analytical task. C-peptide concentrations, on the other hand, tend to be in the
moderate ng/mL range and are hence much easier to determine. Insulin and C-peptide are important
in the diagnostics and management of metabolic disorders such as diabetes mellitus and are also
particularly relevant target analytes in professional sports and forensics. All insulins are classified
on the World Anti-Doping Agency’s (WADA) list of prohibited substances and methods in sports
with a minimum required performance level (MRPL) of 50 pg/mL. Until now, methods combining
immunoextraction and subsequent mass spectrometric detection have mostly been used for this
purpose. With the method developed here, sample preparation has been simplified considerably
and does not require an antibody-based sample purification. This was achieved by a sophisticated
mixed-mode solid-phase extraction and subsequent separation with liquid chromatography coupled
to high-resolution mass spectrometry. Included target insulins were human, lispro, glulisine, aspart,
glargine metabolite, degludec, and additionally, human C-peptide. The method was validated for the
synthetic insulin analogs considering WADA requirements including specificity, limit of detection
(10–25 pg/mL), limit of identification, recovery (25–100%), robustness, carry over (<2%), and matrix
effects. All sample preparation steps were controlled by two stable isotope-labeled internal standards,
namely, [[2H10] LeuB6, B11, B15, B17]-insulin and [[13C6] Leu26, 30] C-peptide. Finally, the method
was applied to samples from patients with diabetes mellitus treated with synthetic insulins.
Keywords: high-resolution mass spectrometry; mixed-mode solid-phase extraction; doping controls
1. Introduction
While insulin is an important, endogenous peptide hormone that regulates blood
glucose homeostasis and other aspects of metabolism, the cosecreted C-peptide owns
merely limited (if any) or unknown physiological effects. C-peptide and insulin are pro-
duced in equimolar amounts from the same single-chain prohormone (proinsulin) in the
pancreatic β-cells [1,2]. The single-chain, linear C-peptide consists of 31 amino acids with
an isoelectric point (pI) of 2.8. In contrast, the structure of insulin is more complex, because
it comprises two peptide chains (α+β-chain) with three disulfide bridges and a total of
51 amino acids (21 α-chain, 30 β-chain) and a pI of 5.3. The amino acid sequences of both
hormones (as well as the synthetic analogs) are shown in Table 1. Here, the comparison
of the sequences illustrates that the differentiation of the respective analogs is enabled
by mass spectrometric approaches by means of their distinct molecular masses and/or
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their diagnostic product ions. All synthetic insulin analogs have their individual and
specific pharmacokinetic profile, which facilitates their usage as therapeutic agents to treat
diabetes mellitus (DM) [3]. Generally, because C-peptide is physiologically largely inert, it
has negligible hepatic clearance and is therefore renally excreted in much higher amounts
than insulin. [4] In contrast, insulin has a plasma half-life of only a few minutes and urinary
concentrations are accordingly very low. The World Anti-Doping Agency (WADA) has set
the minimum required performance level (MRPL) for all insulins to 50 pg/mL, and this
concentration represents by far the lowest MRPL of all prohibited substances, emphasizing
the analytical challenge for these bioactive peptides [5]. The present method is mainly
developed in order to facilitate the analysis of urinary doping control samples for synthetic
insulins. All published methods for the determination of insulin and C-peptide in urine by
means of liquid chromatography/mass spectrometry mainly use immunoaffinity extraction
of the target peptides from the matrix [3,6–12]. These immunoaffinity-enriched sample
aliquots are of highly purified quality and allow for nanoscale liquid chromatography.
The specificity achieved by these assays is outstanding, but these methods suffer from
laborious and time-consuming sample preparation, thereby precluding higher sample
throughput. Therefore, a solid-phase extraction-based assay was desirable to provide
an alternative approach that potentially simplifies the urine preparation procedure and
allows for greater assay scalability. Noteworthy, those assays were already developed for
blood samples recently [13,14]. In the present approach, we aimed at the simultaneous
determination of insulin (human, lispro, glulisine, aspart, glargine metabolite, degludec,
porcine, and bovine) and C-peptide in urine after sample preparation by protein precipi-
tation and mixed-mode cation exchange solid-phase extraction, followed by detection by
liquid chromatography–high-resolution mass spectrometry (LC–HRMS). The long-acting
synthetic insulin analog detemir was not included because it is not excreted into urine and
only the metabolite DesB30 human insulin is detectable here [15]. The main parameters
of the target peptides are summarized in Table 1. Two stable isotopically labeled internal
standards [[2H10] LeuB6, B11, B15, B17]-insulin (human) and [[13C6] Leu26, 30]-C-peptide
(human) were used to control all sample preparation steps.
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Table 1. Main characteristics of all target analytes. Modifications in the amino acid sequence, the protonated molecular ion (precursor) with charge state, and most abundant product ions
(with type as subscription) are in bold. (* stable isotope-labeled amino acids).









Human insulin GIVEQCCTSICSLYQLENYCN—FVNQHLCGSHLVEALYLVCGERGFFYTPKT 5803.6 1452/1162 4+/5+ 226y, 219b, 143a, 345y 2 7.05
Insulin aspart GIVEQCCTSICSLYQLENYCN—FVNQHLCGSHLVEALYLVCGERGFFYTDKT 5821.6 1457/1166 4+/5+ 226y, 219b, 248y, 464y 1 7.02
Insulin glulisine GIVEQCCTSICSLYQLENYCN—FVKQHLCGSHLVEALYLVCGERGFFYTPET 5818.6 1456/1166 4+/5+ 227y, 346y, 199y 1 7.01
Insulin lispro GIVEQCCTSICSLYQLENYCN—FVNQHLCGSHLVEALYLVCGERGFFYTKPT 5803.6 1452/1162 4+/5+ 217y, 230y 2 7.01
Insulin glargine met GIVEQCCTSICSLYQLENYCG—FVNQHLCGSHLVEALYLVCGERGFFYTPKT 5746.6 1438 /1151 4+/5+ 226y, 219b 1 7.09
Insulin degludec GIVEQCCTSICSLYQLENYCN—FVNQHLCGSHLVEALYLVCGERGFFYTPK-γ-L-Glu-Pal 6099.8 1527 4+ 641y, 244y 2 8.00
Porcine insulin GIVEQCCTSICSLYQLENYCN—FVNQHLCGSHLVEALYLVCGERGFFYTPKA 5773.6 1445/1156 4+/5+ 226y, 315y 3 7.06
Bovine insulin GIVEQCCASVCSLYQLENYCN—FVNQHLCGSHLVEALYLVCGERGFFYTPKA 5729.6 1433/1147 4+/5+ 226y, 315y 2 6.99
C-peptide EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ 3018.5 1510 2+ 927, 260y, 785b 3 7.22
labeled insulin GIVEQCCTSICSLYQLENYCN—FVNQHL*CGSHL*VEAL*YL*VCGERGFFYTPKT 5843.9 1462/1170 4+/5+ 226y, 219b, 143a, 345y 4 7.01
labeled C-peptide EAEDLQVGQVELGGGPGAGSLQPLAL*EGSL*Q 3030.6 1516 2+ 939y, 266y, 785b 4 7.21
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2. Results and Discussion
2.1. Liquid Chromatography/Mass Spectrometry
Besides the efficient sample cleanup and concentration by means of the mixed-mode
cation exchange, also the liquid chromatographic and mass spectrometric conditions
require careful selection in order to enable fulfilling all mandatory criteria. Concerning
liquid chromatography, preconcentrating the target peptides on a trapping column before
switching and unloading the trapped analytes onto the analytical column represents an
effective tool to clean up and concentrate a comparably high injection volume (up to 25 µL),
which still contains a comparably high load of inorganic salts and other undesired residues.
On the other hand, the employed high-resolution/high-mass accuracy mass spectrometer
offers the potential to multiplex and group different precursor ions before collision-induced
dissociation. With the knowledge of which product ion is diagnostic to the respective target
analyte, the multiplexing enables fast data acquisition rates with a sufficient number of data
points over the chromatographic peak. Figure 1 shows example chromatograms of a blank
sample from a healthy volunteer; accordingly, a fortified sample (at 25 pg/mL) is illustrated
in Figure 2. While only endogenous human insulin and C-peptide are detected in Figure 1,
all included target peptides were identified in the fortified sample. The presence of insulin
lispro in addition to human insulin (they share the same molecular mass, see Table 1) is
detected by the diagnostic product ion at m/z 217.12.
2.2. Validation
Full method validation was performed as an initial testing procedure according to the
requirements of the ISL [16]. The main results are summarized in Table 2. The specificity
showed that no interfering signals occur for the synthetic insulins when measuring urine
from healthy nontreated volunteers. Here, in all samples, endogenous human insulin
and C-peptide were detected (example see Figure 1). The limits of detection ranged at
approximately 10–25 pg/mL for all target analytes, which is sufficient according to WADA
requirements, where the MRPL is set to 50 pg/mL for all insulin analogs. At this level
(50 pg/mL), the respective signal in the chromatogram was detected for all analogs in
all six different urine samples with a signal to noise ratio (S/N) of >3. The results for
the LOI, determined at 25, 10, and 5 pg/mL (Table 2) show that the synthetic insulins
are largely detectable at 25 pg/mL and only barely at 5 pg/mL. Figure 2 shows a typical
chromatogram from a sample fortified at 25 pg/mL. Typical recoveries range from 26 to
53% (exemption: C-peptide at 100%) with a relative standard deviation between 2 and
24%. The robustness of the method was evaluated according to the drying time in the
heated vacuum centrifuge. Here, it was shown that the target peptides are not suffering
from degradation when they are exposed to heat in the vacuum centrifuge for up to 10 min
after dryness. This represents important information for preparing large sample sets with
different individual drying times.
Carryover from a highly concentrated sample into the next injection was tested at
four times MRPL (200 pg/mL). Here, the maximum carryover for all included target
peptides was below 1–2% of the preceding injection. The impact of matrix effects yielded
no significant ion enhancement or ion suppression (+/−20% rel. std. deviation) in five
different blank samples, compared to a neat standard solution.
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Figure 1. Extracted ion chromatograms of a blank sample from a healthy volunteer showing signals for endogenous human insulin and C-peptide only.
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Figure 2. Extracted ion chromatograms of a human blank sample fortified at 50% of the MRPL with 25 pg/mL for all insulin analogs. C-peptide and human insulin are endogenous and
were not fortified.
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Table 2. Main validation results for all target analytes.














Human insulin ok 10 - - - - 2 35 <1% -
Insulin aspart ok 10 6/6 6/6 4/6 3/6 9 26 <1% 80–120
Insulin glulisine ok 10 6/6 6/6 4/6 3/6 8 26 <2% 80–120
Insulin lispro ok 10 6/6 6/6 5/6 3/6 8 31 <2% 80–120
Insulin glargine met ok 10 6/6 6/6 4/6 2/6 13 39 <1% 80–120
Insulin degludec ok 10 6/6 6/6 5/6 4/6 24 51 <2% 80–120
Porcine Insulin ok 25 6/6 4/6 2/6 0/6 9 34 <2% 80–120
Bovine Insulin ok 10 6/6 6/6 5/6 4/6 10 35 <1% 80–120
C-peptide ok 25 - - - - 3 100 <2% -
2.3. Proof of Concept
The applicability of the method to authentic patient samples was verified with five
human urine samples from a person with diabetes mellitus (DM) receiving synthetic insulin
therapy. Figure 3 shows exemplarily the chromatograms from one person using the fast-
acting insulin aspart (Novorapid) and the ultralong-acting insulin degludec (Tresiba).
Both synthetic insulins were detected in the respective diagnostic product ion trace with
signals at 7.0 min for aspart (m/z 1166 resp. 1457 to 219.15) and at 8.0 min (m/z 1526 to
641) for degludec. The observation that no human insulin and only traces of endogenous
human C-peptide were detected support the diagnosis of type 1 diabetes mellitus, which is
characterized by an absolute endogenous insulin deficiency. Table 3 shows all the main
characteristics and results from the five samples derived from synthetic insulin-treated
patients. All expected insulins were detected in respective samples, which further confirms
the proof-of-concept for the method. The estimated concentrations of all detected insulins
are in the validated working range of the assay.
Table 3. Main characteristics and results for the postadministration sample analysis.
Patient Number Diabetes Type Insulin Regimen Detected Peptides
1 II Tujon (glargine) glargine metabolite, human insulin, C-peptide
2 I Fiasp (aspart), 44 U/d aspart
3 II Fiasp (aspart), tiny doses aspart, human insulin, C-peptide
4 unclear Novorapid, 24 U/d; Lantus 24U/d
aspart, glargine (lantus) metabolite, human insulin,
C-peptide
5 unknown Novorapid, 24 U/d; Tresiba 19U/d aspart, tresiba (degludec), C-peptide (traces)
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Figure 3. Extracted ion chromatograms of a blank sample from a healthy volunteer (left) with endogenous human insulin and C-peptide only. On the right, a postadministration sample
from a patient suffering from diabetes mellitus (type I, patient No 5) with a regular treatment of insulin aspart and degludec. Only traces of endogenous C-peptide as well as no endogenous
human insulin was detected in this sample.
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2.4. Limitations of the Assay/Potential Applications
At the present status of the assays, the data interpretation is focused on qualitative
results only, and a reliable comparison to other assays (e.g., LBA) is not possible. For
example, in doping controls, already the qualitative determination (and confirmation)
of synthetic insulin in a sample from an athlete (nondiabetic without therapeutic use
exemption) constitutes an adverse analytical finding [16]. The same scenario would be valid
for forensic samples from nondiabetic patients (surreptitious administration, medication
errors, etc.). Noteworthy, postmortem urine samples tend to fast degradation of the
synthetic as well as the endogenous insulins if not stored immediately at frozen conditions.
Thus, other matrices (serum, plasma, etc.) might be preferable in situations precluding
immediate postcollection freezing [17]. Generally, also quantification of insulin and C-
peptide might be possible with the present assay but requires further characterization of
the method. At present, the simultaneous, semiquantitative determination of C-peptide
and insulin enables a fast evaluation of endogenous versus exogenous insulin exposure,
including the characterization of the type exogenous insulin and the diagnosis of defective
or suppressed insulin production. Although sample collection is much more convenient
compared to venipuncture, the analysis of urine for peptide-based drugs represents a
challenge due to the variability of the matrix. In contrast to blood (serum or plasma),
the urinary matrix is often not well defined and parameters such as pH, density, protein
content, particulate, etc. vary considerably. Each of these parameters may affect the quality
of the analysis and necessitate careful control, e.g., by monitoring the ISTD, accordingly.
In the case of glargine, the assay is focused on the main metabolite [18]. This might be
adapted in the case of confirmatory analysis.
3. Materials and Methods
Chemicals such as acetonitrile, glacial acetic acid, dimethylsulfoxide, formic acid,
methanol, ammonium hydroxide, porcine insulin, bovine insulin, and [[13C6] Leu26,
30]-C-peptide (human) were obtained from Sigma (Schnelldorf, Germany). All aqueous
buffers and solutions were prepared in purified water (MilliQ quality, Frankfurt, Germany).
Recombinant human insulin was obtained from Aventis (Frankfurt, Germany). The labeled
insulin (internal) standard [[2H10] LeuB6, B11, B15, B17]-insulin (human) was purchased
from PeptaNova (Sandhausen, Germany). The used solid-phase extraction cartridges
OASIS MCX (30 mg, 3 mL) were from Waters (Eschborn, Germany), and the synthetic
insulin analogs lispro (Humalog), aspart (Novorapid), glulisine (Apidra), and insulin
degludec (Tresiba) were supplied by Eli Lilly (Indianapolis, IN, USA), Novo Nordisk
(Princeton, NJ, USA), and Aventis (Kansas City, MO, USA), respectively. The glargine
metabolite (DesB31-32 glargine) was obtained from IBA (Warsaw, Poland).
3.1. Urine Samples
Spontaneous urine samples were collected from healthy volunteers (five male, five
female), without any known medication prior to sampling, and stored frozen until analysis.
These samples were used for the validation (specificity). Here, written consent and approval
from the local ethical committee were obtained (No.: 047/2021). Additionally, spontaneous
urine samples from patients with type 1 or 2 diabetes using different synthetic insulins
(degludec, aspart, and glargine) as part of their usual care were analyzed. Applied doses
varied from 18 to 44 units/day, and the samples were collected as spontaneous urine within
routine diagnostics. All patients provided written informed consent for further use of
their specimens. For this study, 3 mL of urine was used per analysis; the volume might be
adapted if more or less sensitivity is required. The urine samples were not treated with any
protease inhibitors.
3.2. Sample Preparation Mixed-Cation Exchange
To 3 mL of urine, 10 µL of internal standard solution (containing 0.5 µg/mL labeled
insulin and 10 µg/mL labeled C-peptide), 1 mL of a mixture of acetonitrile/methanol
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(1/1, ice cold), and 50 µL of glacial acetic acid was added. After a short vortex, the
sample was centrifuged for 10 min at 4000× g, and the supernatant was transferred to
a new 10 mL polypropylene tube. Solid-phase extraction was performed with mixed-
mode cation-exchange cartridges (Waters MCX, 3 cm, 30 mg), which were preconditioned
with 1 mL of methanol and 1 mL of water prior to load with the sample solution in two
steps. The samples were washed with 2 mL of water and 2 mL of methanol (acidified
with 2% of acetic acid; this mixture is freshly prepared every working day). Finally,
the sample was eluted into a new 1.5 mL Eppendorf tube with 1.2 mL of a mixture of
methanol/ammonium hydroxide solution (5:1), and the volume was reduced to near
dryness in a vacuum centrifuge. The residue was diluted with 80 µL of aqueous acetic acid
(1%), and 15–25 µL were injected into the LC-MS system.
3.3. Liquid Chromatography
Chromatographic separation of the target analytes was conducted by high-performance
liquid chromatography using a Vanquish system (Thermo, Bremen, Germany). The system
was equipped with a dual-pump setup and initial trapping of the target analytes on a
short trapping column Accucore Phenyl/Hexyl, 3 × 10 mm, 2.7 µm PS (Thermo, Bremen,
Germany) using a water solution of formic acid (0.1%, solvent A1) and acetonitrile (with
0.1% formic acid, solvent B1). Trapping was performed for 2 min at 99% of solvent A1
before switching the flow to the analytical column. Since solvent buffers A2 and B2 for
generating the gradient, water solution of formic acid (0.1%, with 1% of DMSO, solvent
A2) and acetonitrile with DMSO (1%), and water solution of formic acid (0.1%) (solvent
B2) were used. As analytical column, a Poroshell C18 3 × 50 mm (Agilent, Karlsruhe,
Germany) was utilized, and the flow was set to 400 µL/min. The gradient started at 99%
A2 and decreased to 40% A2 within 8 min. Within the next 2 min, the gradient decreased
to 20% A2 for cleaning the column. Finally, the system was reequilibrated for 5 min at
starting conditions. The resulting overall run time was 15 min, and the injection volume
was 15–25 µL. The column compartment was set to 25 ◦C.
3.4. Mass Spectrometry
An Orbitrap Exploris 480 high-resolution mass spectrometer (Thermo, Bremen, Ger-
many), equipped with a heated electrospray ion source, was used for the detection of the
target peptides. The instrument was operated in positive ionization mode acquiring data
in full scan mode (m/z = 400–1700, resolution 60,000 FWHM) and targeted MS2 by means
of an inclusion list. Targeted MS2 (PRM) experiments were performed for the multiply
protonated molecules of the target peptides and multiplexed four times with a quadrupole
isolation window of 2 m/z units. The targeted MS2 experiments were acquired with a resolu-
tion of 45,000 FWHM. Multiplex groups were defined as follows: Group 1: aspart, glulisine,
glargine metabolite; group 2: lispro, bovine, degludec; group 3: porcine, C-peptide; group 4:
ISTD insulin and ISTD C-peptide. For all insulin analogs, the respective five- and fourfold
protonated precursor ions were used for MS2 experiments (except degludec: fourfold
protonated precursor only). For C-peptide and the respective ISTD, the doubly charged
precursor ion was used. The corresponding diagnostic product ions are listed in Table 1.
The instrument was calibrated according to the manufacturer‘s recommendations using a
calibration mixture (consisting of caffeine, the tetrapeptide MRFA, and Ultramark). The
gas supply consisted of nitrogen (N2-generator, CMC, Eschborn, Germany). Ionization
in positive mode was accomplished at a voltage of 3 kV, and the temperature of the ion
transfer tube was adjusted to 320 ◦C. Xcalibur Software used was: Foundation 3.1SP7 QF1,
Xcalibur 4.4 (Thermo, Bremen, Germany) Main characteristics of the target analytes are
summarized in Table 1.
3.5. Validation
The validation of the assay was performed under consideration of qualitative re-
sult interpretation and the requirements of the WADA (ISL 11) including the parameters
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specificity, limit of detection (LOD), limit of identification (LOI), linearity, recovery, carry-
over, matrix effects, and robustness [16]. Urine from healthy volunteers (for all synthetic
analogs) and from a patient with longstanding type 1 diabetes mellitus (for human insulin and
C-Peptide) were used.
3.5.1. Specificity
The specificity of the method was demonstrated by 10 blank urine samples from 10
healthy volunteers (five male, five female), who were proven not to receive a therapeutic
insulin regimen.
3.5.2. Recovery
In order to demonstrate the recovery of target analytes during processing samples
were prepared as follows. Six blank urine samples were spiked at 100 pg/mL of all target
analytes before processing and six further samples were spiked after processing prior
injection into the LC–MS. With the comparison of the results, the recovery of the method
was calculated in percent. The recovery for human insulin and C-peptide was determined
with a urine sample from a person with type 1 diabetes.
3.5.3. Limit of Detection/Limit of Identification (LOD/LOI)
The limit of detection was determined in a representative blank urine sample fortified
with 0, 5, 10, 25, and 50 pg/mL of all target analytes. The signal-to-noise ratio (S/N) at the
respective retention time was evaluated for all target analytes. Noteworthy, for evaluation
of the LOD for human insulin and C-Peptide, a urine sample from a person with type 1
diabetes was used. The limit of identification (LOI) was calculated by fortifying six different
urine samples (from healthy volunteers) at 5, 10, 25, and 50 pg/mL (corresponding to 10,
20, 50, and 100% of the MRPL) with all synthetic insulin analogs.
3.5.4. Precision
Relative standard deviations of the peak area ratios from a sixfold determination of
fortified sample aliquots (at 100 pg/mL) were calculated to show the precision of the assay.
3.5.5. Carry-Over
A possible carryover of analyte from one sample to the next was investigated by
injecting a blank sample after a spiked sample from the upper working range (500 pg/mL)
and inspecting the respective chromatograms for possible carryover signals.
3.5.6. Matrix Effect
The comparison of the signal intensities of five processed blank urine samples that
were subsequently spiked with all target analytes with a neat standard aliquot that does
not contain any matrix is used to determine the matrix effects.
3.5.7. Robustness
One of the critical steps is the degradation of the peptides in the vacuum centrifuge;
thus, the impact of the drying time was evaluated for the different peptides. Therefore, six
fortified sample aliquots (spiked at 100 pg/mL) were evaporated in the vacuum centrifuge
to near dryness (two aliquots), to dryness (two aliquots), and to dryness plus 15 min (two
aliquots).
4. Conclusions
In summary, the method shown here can be used for simplified qualitative deter-
mination of insulin and its synthetic or animal analogs and C-peptide in urine samples.
Due to its noninvasive and convenient sample collection, the method may open new di-
agnostic avenues, especially in the field of pediatrics. The method fulfills the criteria for
doping control analysis considering the MRPL of 50 pg/mL while allowing for omission
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of immunoaffinity purification steps, which provides a considerable benefit in terms of
sample preparation efficiency for the initial testing and the majority of samples are tested
negative. Nevertheless, in the case of confirmatory analysis in doping controls, applying
the additionally established immunoaffinity-based LC–MS test methods is strongly recom-
mended due to commonly superior LODs and enhanced specificity. This is especially true
for samples with unknown and uncontrolled backgrounds/origins (such as doping control
samples or forensic cases).
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